JP2015529652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529652A5 JP2015529652A5 JP2015524600A JP2015524600A JP2015529652A5 JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5 JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- deuterium
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C Chemical compound CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C 0.000 description 5
- YIINKKNBXUALQJ-CPPUAGTESA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O YIINKKNBXUALQJ-CPPUAGTESA-N 0.000 description 1
- LQKWQBFFAXGZOK-WPZYDENFSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O LQKWQBFFAXGZOK-WPZYDENFSA-N 0.000 description 1
- JWJIPZPFNNVDPQ-BSDZSUBPSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O JWJIPZPFNNVDPQ-BSDZSUBPSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210273491 | 2012-08-03 | ||
| CN201210273491.8 | 2012-08-03 | ||
| CN201310116933 | 2013-04-03 | ||
| CN201310116933.2 | 2013-04-03 | ||
| PCT/CN2013/000915 WO2014019344A1 (en) | 2012-08-03 | 2013-08-05 | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529652A JP2015529652A (ja) | 2015-10-08 |
| JP2015529652A5 true JP2015529652A5 (enExample) | 2016-09-23 |
Family
ID=50027184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524600A Pending JP2015529652A (ja) | 2012-08-03 | 2013-08-05 | Ｃ型肝炎阻害剤である架橋環化合物及びその医薬品への応用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9309231B2 (enExample) |
| EP (1) | EP2880030B1 (enExample) |
| JP (1) | JP2015529652A (enExample) |
| KR (1) | KR20150039200A (enExample) |
| CN (1) | CN103570693B (enExample) |
| AU (1) | AU2013299246B2 (enExample) |
| BR (1) | BR112015000420A2 (enExample) |
| CA (1) | CA2872118A1 (enExample) |
| MX (1) | MX2015001571A (enExample) |
| MY (1) | MY187617A (enExample) |
| RU (1) | RU2015107043A (enExample) |
| SG (1) | SG11201406824XA (enExample) |
| TW (1) | TWI610916B (enExample) |
| WO (1) | WO2014019344A1 (enExample) |
| ZA (1) | ZA201407779B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| BR112016011727A2 (pt) | 2013-11-22 | 2017-08-08 | CL BioSciences LLC | Antagonistas de gastrina para o tratamento e prevenção de osteoporose |
| WO2015110048A1 (en) * | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| CN107954997A (zh) * | 2014-02-21 | 2018-04-24 | 常州寅盛药业有限公司 | 作为丙肝病毒抑制剂的联环化合物 |
| CN105384792B (zh) * | 2014-08-23 | 2020-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| TWI675029B (zh) * | 2014-12-16 | 2019-10-21 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的橋環化合物及其製備方法 |
| TWI703141B (zh) * | 2015-03-12 | 2020-09-01 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的化合物及其在藥物中的應用 |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| EP3589633A1 (en) * | 2017-03-02 | 2020-01-08 | Wockhardt Limited | Heterocyclic derivatives as antibacterial compounds |
| EP3706740A4 (en) * | 2017-11-06 | 2021-07-28 | Suzhou Pengxu Pharmatech Co., Ltd. | METHOD FOR MANUFACTURING ACALABRUTINIB |
| US11634389B2 (en) | 2018-11-28 | 2023-04-25 | The Regents Of The University Of Michigan | Succinate dehydrogenase inhibitors and methods of making and using the same |
| US20220227729A1 (en) | 2019-05-21 | 2022-07-21 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CN111118073B (zh) * | 2019-12-27 | 2022-02-15 | 宜昌东阳光生化制药有限公司 | 酶法合成依米他韦中间体的方法 |
| CN114929228A (zh) * | 2020-01-03 | 2022-08-19 | 布鲁奥科制药有限公司 | 用于治疗cns病症的化合物和组合物 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| GB202013383D0 (en) * | 2020-08-26 | 2020-10-07 | Givaudan Sa | Process |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3019259A (en) * | 1959-11-02 | 1962-01-30 | Dow Chemical Co | 1, 4-dihydro-1, 4-methanonaphthalene-5, 8-diamine |
| US3268581A (en) * | 1964-05-08 | 1966-08-23 | Dow Chemical Co | Anthraquinone dialkanesulfonimide |
| US3493616A (en) * | 1967-02-27 | 1970-02-03 | Universal Oil Prod Co | Hydroxy and/or hydrocarbyloxy and amino-alkano-tetrahydronaphthalenes |
| US3835104A (en) * | 1968-09-05 | 1974-09-10 | Snam Progetti | Curable,amorphous,olefinic terpolymers from alphamono olefins and polyenes |
| US4009200A (en) * | 1973-02-02 | 1977-02-22 | Uniroyal, Inc. | Hexahalo-1,4-dihydro-1,4-methano-napth-5,8-ylene acetates |
| JPS60152435A (ja) * | 1984-01-20 | 1985-08-10 | Dainippon Ink & Chem Inc | ２，３−ジアセチルノルボルナジエンとその製造法 |
| US7291689B1 (en) * | 2006-05-01 | 2007-11-06 | Seoul National University Industry Foundation | Thermally stable low dielectric norbornene polymers with improved solubility and adhesion property |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA024853B1 (ru) | 2008-12-03 | 2016-10-31 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
| AU2009322387A1 (en) | 2008-12-03 | 2011-06-30 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| EP2393359A4 (en) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
| US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
| CN102427731B (zh) * | 2009-02-27 | 2015-05-13 | 英安塔制药有限公司 | 丙型肝炎病毒抑制剂 |
| RS54713B1 (sr) | 2009-03-27 | 2016-08-31 | Merck Sharp & Dohme Corp. | Inhibitori replikacije virusa hepatitisa c |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| CN102427726B (zh) | 2009-03-27 | 2014-10-08 | 普雷西迪奥制药公司 | 丙型肝炎的稠环抑制剂 |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| EA027493B1 (ru) * | 2009-05-13 | 2017-07-31 | Джилид Фармассет Ллс | Промежуточные соединения для получения противовирусного соединения |
| SG176137A1 (en) | 2009-05-18 | 2011-12-29 | Actelion Pharmaceuticals Ltd | Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists |
| US8772505B2 (en) * | 2009-05-29 | 2014-07-08 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| BR112012014899A2 (pt) | 2009-12-18 | 2017-03-14 | Idenix Pharmaceuticals Inc | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus |
| AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
| EP2515902A1 (en) | 2009-12-24 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010919A (es) | 2010-03-24 | 2013-02-01 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CA2802067A1 (en) | 2010-06-09 | 2011-12-15 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a protein |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012003642A1 (en) | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| JP2013541499A (ja) | 2010-07-26 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法 |
| ES2504977T3 (es) | 2010-07-26 | 2014-10-09 | Janssen R&D Ireland | Derivados hetero-bicíclicos como inhibidores del VHC |
| MX341394B (es) * | 2010-07-29 | 2016-08-18 | Astellas Pharma Inc | Compuesto de piridina de anillo fusionado. |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| AR082619A1 (es) | 2010-08-13 | 2012-12-19 | Hoffmann La Roche | Inhibidores del virus de la hepatitis c |
| AU2011307953B2 (en) | 2010-09-29 | 2014-07-31 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives for treating hepatitis C virus infection |
| AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| WO2012041227A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds for treating hepatitis c viral infection |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012083053A2 (en) | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| US20150158909A1 (en) | 2010-12-15 | 2015-06-11 | Abbevie Inc. | Anti-viral compounds |
| MX2013006828A (es) | 2010-12-16 | 2014-10-14 | Abbvie Inc | Compuestos antivirales. |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| TWI482766B (zh) * | 2011-07-09 | 2015-05-01 | Sunshine Lake Pharma Co Ltd | As a spiro compound for hepatitis C virus inhibitors |
| PH12014500311A1 (en) | 2011-08-08 | 2014-03-31 | Lupin Ltd | Antiviral compounds with a fused tricyclic ring |
| US8889726B2 (en) | 2011-08-08 | 2014-11-18 | Glaxosmithkline Llc | Chemica compounds |
-
2013
- 2013-08-02 TW TW102127866A patent/TWI610916B/zh active
- 2013-08-05 BR BR112015000420A patent/BR112015000420A2/pt not_active IP Right Cessation
- 2013-08-05 MY MYPI2014703257A patent/MY187617A/en unknown
- 2013-08-05 SG SG11201406824XA patent/SG11201406824XA/en unknown
- 2013-08-05 AU AU2013299246A patent/AU2013299246B2/en not_active Ceased
- 2013-08-05 CA CA2872118A patent/CA2872118A1/en not_active Abandoned
- 2013-08-05 KR KR20157002654A patent/KR20150039200A/ko not_active Withdrawn
- 2013-08-05 WO PCT/CN2013/000915 patent/WO2014019344A1/en not_active Ceased
- 2013-08-05 JP JP2015524600A patent/JP2015529652A/ja active Pending
- 2013-08-05 CN CN201310337556.5A patent/CN103570693B/zh active Active
- 2013-08-05 EP EP13824843.0A patent/EP2880030B1/en not_active Not-in-force
- 2013-08-05 US US14/397,200 patent/US9309231B2/en not_active Expired - Fee Related
- 2013-08-05 RU RU2015107043A patent/RU2015107043A/ru not_active Application Discontinuation
- 2013-08-05 MX MX2015001571A patent/MX2015001571A/es unknown
-
2014
- 2014-10-24 ZA ZA2014/07779A patent/ZA201407779B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529652A5 (enExample) | ||
| AU2018202581B2 (en) | Combination of direct acting antiviral agents and ribavirin for treating HCV patients | |
| US20130072528A1 (en) | Methods for Treating HCV | |
| RU2015107043A (ru) | Соединенные циклические соединения как ингибиторы вируса гепатита с (вгс) и их фармацевтическое применение | |
| AU2022209336A1 (en) | Methods for treating HCV | |
| US20130172240A1 (en) | Methods for treating hcv | |
| JP2013535487A5 (enExample) | ||
| US20150011481A1 (en) | Methods for Treating HCV | |
| WO2016134054A1 (en) | Anti-viral compounds | |
| EP2416765B1 (en) | Hcv inhibitor and therapeutic agent combinations | |
| US20140024613A1 (en) | Methods for Treating HCV | |
| US20160317603A9 (en) | Methods for Treating HCV | |
| WO2016134056A1 (en) | Anti-viral compounds | |
| WO2017040892A1 (en) | Anti-viral compounds | |
| WO2016182935A1 (en) | Anti-viral compounds | |
| WO2016134057A1 (en) | Anti-viral compounds | |
| WO2016182936A1 (en) | Anti-viral compounds | |
| US20180042982A1 (en) | Methods for Treating HCV | |
| WO2019074507A1 (en) | METHODS FOR THE TREATMENT OF HCV | |
| WO2019027694A1 (en) | METHODS OF TREATING HCV | |
| WO2016182938A1 (en) | Anti-viral compounds |